1
|
Duan MH, Li ZE, Zhang YN, Jin YG, Liu Y, Li XP, Yang F. In vitro antibacterial activity of danofloxacin against Escherichia coli isolated from pigeons and its pharmacokinetic in pigeons. Poult Sci 2024; 103:104168. [PMID: 39137498 PMCID: PMC11372714 DOI: 10.1016/j.psj.2024.104168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2024] [Revised: 07/28/2024] [Accepted: 07/30/2024] [Indexed: 08/15/2024] Open
Abstract
This experiment aimed to investigate the in vitro antimicrobial activity of danofloxacin against Escherichia coli (E. coli) isolated from pigeons, as well as the pharmacokinetics of danofloxacin in pigeons following oral (PO), intramuscular (IM), and intravenous (IV) administration. The minimum inhibitory concentration (MIC) of danofloxacin was first determined for 38 clinical E. coli strains using the micro broth dilution method. Subsequently, 30 healthy pigeons were weighed and randomly divided into 3 groups: IM, IV, and PO, with 10 pigeons in each group. Danofloxacin was given at 5 mg/kg body weight (BW) through 3 different routes. Blood was collected, and plasma was separated at various time points from 0 to 48 h. Plasma samples were analyzed for danofloxacin concentrations using a validated HPLC method. Pharmacokinetic analysis was performed using Phoenix software and a noncompartmental analytical (NCA) method. The results indicated that danofloxacin had a strong antibacterial effect on E. coli, with a MIC50 of 0.5 μg/mL. The noncompartmental analysis showed that after PO and IM administration at 5 mg/kg in pigeons, peak plasma concentrations (Cmax) of 0.61 and 1.62 μg/mL were reached at 4.5 and 0.53 h, respectively. The oral and intramuscular bioavailability (F) were 68.08% ± 24.82% and 87.82% ± 25.36%, respectively. Following IV administration, danofloxacin was widely distributed in pigeons, with volume of distribution (VZ) and volume of distribution at steady state (VSS) values of 6.11 ± 2.01 and 4.65 ± 1.62 L/kg, respectively, and was eliminated slowly, with an elimination half-life (t1/2λz) of 6.41 ± 2.15 h. Based on the calculated ratio values of AUC/MIC, the current IV, IM, and PO doses of 5 mg/kg of danofloxacin would be expected to effectively treat pigeons infected with E. coli strains with MIC values equal to or less than 0.5 μg/mL.
Collapse
Affiliation(s)
- Ming-Hui Duan
- Laboratory of Veterinary Drug Development and Evaluation, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, 471023, China
| | - Ze-En Li
- Laboratory of Veterinary Drug Development and Evaluation, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, 471023, China
| | - Yan-Ni Zhang
- Laboratory of Veterinary Drug Development and Evaluation, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, 471023, China
| | - Yang-Guang Jin
- Laboratory of Veterinary Drug Development and Evaluation, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, 471023, China
| | - Yue Liu
- Laboratory of Veterinary Drug Development and Evaluation, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, 471023, China
| | - Xing-Ping Li
- Laboratory of Veterinary Drug Development and Evaluation, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, 471023, China
| | - Fan Yang
- Laboratory of Veterinary Drug Development and Evaluation, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, 471023, China.
| |
Collapse
|
2
|
Chen JC, Liang J, Li ZE, Duan MH, Dai Y, Jin YG, Zhang YN, Liu Y, Zhang M, Wang GY, Yang F. In vitro antibacterial activity of danofloxacin against Escherichia coli in Gushi chickens and its residue depletion following multiple oral administration. Poult Sci 2024; 103:103493. [PMID: 38335674 PMCID: PMC10864797 DOI: 10.1016/j.psj.2024.103493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2024] [Revised: 01/18/2024] [Accepted: 01/19/2024] [Indexed: 02/12/2024] Open
Abstract
This study aimed to investigate the in vitro antibacterial activity of danofloxacin against Escherichia coli isolated from Gushi chickens, as well as the tissue distribution and residue depletion of danofloxacin in Gushi chickens following multiple oral administration. A total of 42 clinical E. coli strains were isolated from the cloaca of locally farmed Gushi chickens between August and October 2023. Then the minimum inhibitory concentration (MIC) of danofloxacin against these isolates was determined by broth microdilution method. Additionally, 42 healthy Gushi chickens were randomly divided into 6 groups, and danofloxacin was orally administered at a dose of 5 mg/kg body weight (BW) for 3 consecutive days. Plasma, intestinal content, and tissue samples, including muscle, skin + fat, liver, kidney, lung, and intestine, were collected at 4, 12, 24, 48, 72, and 120 h after the last administration. Danofloxacin concentrations in all samples were determined using a high-performance liquid chromatography (HPLC) method. The average concentration vs. time data were then subjected to noncompartmental analysis using Phoenix software, and withdrawal periods for danofloxacin in Gushi chickens were further determined with WT1.4 software, setting a 95% confidence interval. Results indicated a notable inhibitory effect of danofloxacin on E. coli, with an MIC50 of 0.5 μg/mL. Additionally, danofloxacin exhibited widespread distribution in Gushi chickens, detectable in all collected samples. Among all tissues, the liver exhibited the highest concentration, followed by the intestine. Even on the fifth day postadministration, danofloxacin persisted in skin + fat, liver, and lung. The elimination half-lives (t1/2λzs) of danofloxacin varied across samples: skin + fat (47.87 h), lung (30.61 h), liver (22.07 h), plasma (16.05 h), muscle (12.53 h), intestine (9.83 h), and kidney (6.34 h). Considering residue depletion and the maximum residue limit (MRL) of danofloxacin in poultry set by Chinese regulatory authorities, withdrawal periods for the kidney, muscle, liver, and skin + fat were determined as 1.03, 1.38, 3.34, and 5.85 d, respectively, rounded to a final withdrawal time of 6 d.
Collapse
Affiliation(s)
- Jun-Cheng Chen
- College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China
| | - Jun Liang
- Zhengzhou Institute of Veterinary Drug and Feed Control, Zhengzhou 450002, China
| | - Ze-En Li
- College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China
| | - Ming-Hui Duan
- College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China
| | - Yan Dai
- College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China
| | - Yang-Guang Jin
- College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China
| | - Yan-Ni Zhang
- College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China
| | - Yue Liu
- College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China
| | - Mei Zhang
- College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China
| | - Guo-Yong Wang
- College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China
| | - Fan Yang
- College of Animal Science and Technology, Henan University of Science and Technology, Luoyang 471023, China.
| |
Collapse
|